Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis
Open Access
- 3 July 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 28 (1) , 106-111
Abstract
The treatment of lupus nephritis (LN) remains problematic because the current treatment regimen based on unspecific immunosuppressants such as steroids, cyclophosphamide and mycophenolate has significant side effects and is often inefficient. B-cell ablation with the chimeric anti-CD20 antibody rituximab (RTX) has been considered as an alternative treatment option but the randomized controlled LUNAR trial failed to show any additive effect of RTX beyond a steroid–mycophenolate mofetil (MMF) combination for LN type III/IV/V in incident patients. At present, no such trial is available for the use of RTX in refractory LN. We analysed existing evidence on this topic by performing a systematic analysis of reports that document outcomes of RTX treatment for refractory LN. Out of 233 reports, we selected 26 for analysis, which described 300 patients with a mean follow-up of 60 weeks. The complete or partial response criteria were met by 87% of patients with LN class III, 76% with class IV and 67% with class V, respectively. Mixed classes responded in 76% of patients. RTX induced complete responses in 60% (type III), 45% (type IV), 40% (type V) and 24% (mixed types), respectively. Our systematic review of existing evidence suggests that RTX effectively induces remission of LN in patients who have not achieved remission with standard therapies. Another randomized controlled trial should be conducted to test the efficacy of RTX in refractory LN.Keywords
This publication has 39 references indexed in Scilit:
- Basic and Translational Concepts of Immune-Mediated Glomerular DiseasesJournal of the American Society of Nephrology, 2012
- A novel pathogenetic concept—antiviral immunity in lupus nephritisNature Reviews Nephrology, 2012
- IRF4 Deficiency Abrogates Lupus Nephritis Despite Enhancing Systemic Cytokine ProductionJournal of the American Society of Nephrology, 2011
- Assessment of a lupus nephritis cohort over a 30-year periodRheumatology, 2011
- Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: Past, present, and futureAutoimmunity, 2009
- Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus NephritisJournal of the American Society of Nephrology, 2009
- The Classification of Glomerulonephritis in Systemic Lupus Erythematosus RevisitedJournal of the American Society of Nephrology, 2004
- Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2002
- A Novel Mouse with B Cells but Lacking Serum Antibody Reveals an Antibody-independent Role for B Cells in Murine LupusJournal of Experimental Medicine, 1999
- Therapy of Lupus NephritisNew England Journal of Medicine, 1986